Last edition
News about "Nelson Ambrogio"
US FDA Grants Priority Review to HYRNUO for HER2-Mutated NSCLC
The US FDA has granted Priority Review (PR) to HYRNUO (sevabertinib) as a first-line treatment for HER2-mutated Non-Small Cell Lung Cancer (NSCLC), based on phase 1/2 SOHO-01 trial data.
Nelson Ambrogio | 21/05/2026 | By News Bureau
Bayer to Showcase Low-Dose MRI Contrast Innovation at ECR 2026
Bayer brings next-generation contrast agents and smart radiology solutions to ECR 2026, spotlighting progress in low-dose MRI imaging and clinical innovation.
Nelson Ambrogio | 28/01/2026 | By News Bureau | 381
Bayer to Enter Molecular Imaging, Acquires Pan-Amyloid Radiotracers from Attralus
By acquiring AT-01 and AT-05 from Attralus, Bayer strengthens its molecular imaging and cardiovascular precision medicine portfolio, targeting earlier and more accurate diagnosis of amyloidosis.
Nelson Ambrogio | 14/01/2026 | By News Bureau | 212
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy